Receptos files for $86.3m IPO
This article was originally published in Scrip
Receptos intends to raise $86.3 million in an initial public offering to fund mid-stage clinical trials for its once-daily, oral multiple sclerosis drug RPC1063 and the antibody RPC4046 for the treatment of eosinophilic esophagitis (EoE).
You may also be interested in...
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.
Public Company Edition: Benefitting from hope that biopharma interventions will help the coronavirus pandemic, the industry is faring better than others in the stock market, including the ability to launch IPOs. Also, BridgeBio leads recent financings and PDL is on track to dissolve by year-end.
Biopharma companies struggle with which trials, if any, to pause or delay. Lilly said it wants to ease the burden on health care facilities, while Galapagos said its choice is related to patient safety.